All News

PQA's program is focused on quality measurement and improving the safe and appropriate use of medications.

Organizations should focus on improving employee well-being and reducing workplace stressors.

This week, Suzanne Soliman, PharmD, BCMAS, is joined by guests Joanna Catravas, PharmD, BCMTMS, and Lisa Scholz, PharmD, MBA, FACHE, to discuss nontraditional roles for pharmacists.

Studies have estimated that 16% of people with dementia experience depression, but this may be as high as 40%, demonstrating a great need for effective treatments.

With climate change potentially affecting pollen counts, new OTC products can relieve symptoms.

Aklilu Tedla, vice president of strategy and business development at Cardinal Health, discusses the future of pharmacies as more cell and gene therapy products become available to patients.

Scientific abstracts also address findings on cardiovascular disease and population, the connection between COVID-19 and HF, and links between prognosis and marital status.

The advisory, published in Circulation, is a call to action for a cultural shift to identify and remove barriers.

Individuals with type 2 diabetes who use insulin are often restricted when accessing continuous glucose monitoring systems.

Long-term extension trial results show a consistent safety profile and durable efficacy for the treatment of adults with the skin condition.

Obeticholic acid (Ocaliva) is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.

With more than 80,000 retail and outpatient pharmacy locations, pharmacists are the most accessible health care professionals in the United States.

PQA is working on developing measures specifically for evaluating pharmacy performance measurement.

Serotonin syndrome generally occurs within 6 hours of a change in dose or addition of medication.

Repotrectinib awarded breakthrough therapy designation for patients with ROS1-positive metastatic non–small cell lung cancer previously treated with a ROS1 tyrosine kinase inhibitor and who were not previously administered platinum-based chemotherapy.

A significantly greater proportion or patients treated with either 15 or 30 mg show remission or endoscopic response or remission at week 52 compared with the placebo.

The SKYSCRAPER-01 trial evaluating the drug plus Tecentriq demonstrates that it did not meet its co-primary endpoint of progression-free survival.

Mesalamine is used to treat and prevent flare-ups of mild to moderately active ulcerative colitis.

Public health and pharmacy work hand-in-hand when it comes down to the ever changing roles for pharmacists and improving expanded scope of practice.

They should consider many factors and use clear guidance on predicting phenotypes from genotypes to intervene optimally based on specific drug-gene interactions.

Delafloxacin (Baxdela) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by designated susceptible bacteria.

BC MAX Strength Fast Pain Relief Powders work fast to relieve tough headaches, body aches, aches and pains, and menstrual cramps.

Neil Lund, senior advisor, Avelere Health and Ryan Urgo, managing director, Health Policy, Avelere Health, discuss the impact of President Biden’s health care agenda on the pharmacy field.

Doug Long, vice president, Industry Relations, IQVIA, discusses notable trends reshaping specialty pharmaceutical channels and the impact of these developments on the role of the pharmacist in the health care team.

The SDOH resource guide focuses on services specific to the pharmacy and pharmacists.

Researchers also noted the importance of patient-reported outcomes due to the fluctuating and unpredictable nature of generalized myasthenia gravis and the subjectivity of symptoms.

The results of a network analyses show that the elevated potential of contracting the virus is also linked to infliximab and tofacitinib, as well as several combination treatments.

Analysis also indicates that individuals with the highest-level beta-cryptoxanthin in their blood were less likely to develop cognitive issues decades later.